- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy of Bylvay (odevixibat) in pruritus, bile acids and sleep with a low drug-related diarrhea rate - Data submitted…
BOSTON, 30 nov. 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq : ALBO), une société spécialisée dans les maladies rares qui développe de nouveaux modulateurs d'acides biliaires pour traiter les maladies du foie chez les enfants et…
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late breaker provides evidence of disease modification in PFIC – Analysis of PEDFIC 1 data showed restoration of bile…
Hochgradige statistisch signifikante Linderung von Juckreiz, dem primären Endpunkt (p=0,002)Signifikante Verringerung des Gallensäurespiegels im Serum, dem wichtigsten sekundären Endpunkt (p=0,001)Erhebliche Verbesserungen bei multiplen…
Miglioramento statisticamente molto significativo dell'endpoint primario del prurito (p=0,002)Significative riduzioni dell'endpoint chiave secondario dei livelli di acidi biliari nel siero (p=0,001)Notevoli miglioramenti in diversi…
Mejoría estadísticamente muy significativa en el criterio de valoración principal «prurito» (p = 0,002)Reducciones significativas en el criterio de valoración secundario clave «niveles de ácidos biliares séricos» (p = 0,001)Mejorías…
– Only once-daily drug indicated for the treatment of pruritus in PFIC – – Commercial launch of Bylvay immediate; available for prescription in the coming days – – Rare Pediatric Disease Priority Review Voucher issued to Albireo by the …